Author: Becca Bucci
AMCP 2023
AAOS – 米国整形外科学会
Therapeutic Proteins’ Drug-Drug Interactions: 最新情報および課題
Therapeutic proteins (TP) – and more specifically monoclonal antibodies – are part of the therapeutic arsenal for the treatment of several diseases, providing effective and safe therapeutic solutions for patients. As part of the usual therapeutic practice, patients often receive drug combinations (TP/TP or TP/small molecules) and/or concomitant co-medications. Thus, drug-drug-interactions (DDIs) can be a … Continued
ACCAE (Asia Congress for Alternatives to Animal Experiments)
Biotech Showcase
BIO Partnering at JPM
Why you should select your drug formulation before starting clinical studies
Drug developers often rush through the discovery process to get into human testing. Most are so curious about their new target or molecule that they may forget that the pharmaceutical formulation process that can easily make or break their program. Once in human testing, revisiting these formulations is often time-consuming. By then, depending on drug … Continued
クラウド環境を活用してワークフローを効率化するには
Certara’s Phoenix Hosted package provides your PK scientists with a secured and validated Certara AWS workspace allowing for much quicker transit time from compliant data sources. It enhances productivity and supports compliance requirements by managing complex time-based data, the foundation for all PK/PD modeling. Certara’s deployment experts can optimize the Phoenix application configuration for increased … Continued
RAPS sponsored webcast: The EU Clinical Trials Regulation – Challenges Drug Developers Faced in the First 6 months
Join us on November 10th for this webcast being held in partnership with RAPS. The Clinical Trials Regulation (CTR) for the European Union (EU) took effect on 2022年1月31日. Sites and sponsors must now embrace the new regulations to successfully run clinical trials across the European Union. Beginning on January 31st, 2023, sponsors are … Continued